FibroBiologics, Inc. (FBLG) AI Stock Analysis

• Market Cap: $42.85M
• Dividend Yield: N/A
• Average Volume (3M): 206.99K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.42
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 13
• Sector: General
• Sector Strength: N/A
• Industry: Biotechnology
• EPS (TTM): -0.34
• Shares Outstanding: 38,262,585
• 10 Day Avg. Volume: 292,423
• 30 Day Avg. Volume: 206,989
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 1.51
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -147.81
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $12.00
• Price Target Upside: 971.43% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

FibroBiologics, Inc. is in a challenging position typical for early-stage biotech firms. The company's financials indicate ongoing losses and reliance on external financing, which is a major risk factor. Technical indicators suggest slight momentum but also highlight resistance levels due to its price position below key moving averages. The valuation reflects the unprofitable nature of the firm with no dividend to attract income-focused investors. These factors combined result in a low stock score, emphasizing the company's need for a clear path to revenue generation.

Positive Factors

Clinical Trials

The planned Phase 1/2 trial in Australia for DFU patients is anticipated to be completed by the end of 2025, which is viewed as a relatively near-term catalyst for supportive validation of fibroblast benefit in diabetic wound healing.

Market Opportunity

Chronic wound care represents a sizable market with $28B in healthcare spending, providing a significant opportunity for FibroBiologics.

Therapy Advancement

Fibroblast therapy could provide improved wound healing quality with superior and timely wound size reduction based on preclinical development.

Negative Factors

Financial Performance

Fibrobiologics reported 3Q24 results with an operating loss of ($3.4M) and cash of $7.8M.

Funding Concerns

The company is expected to be funded into mid-2025.

FibroBiologics, Inc. Business Overview & Revenue Model

Company Description

FibroBiologics, Inc. (FBLG) is a biotechnology company focused on developing and commercializing advanced cellular therapies that leverage fibroblast cells for regenerative medicine. The company operates in the biotechnology sector, emphasizing the development of therapies for various medical conditions, including chronic diseases and degenerative disorders. FibroBiologics aims to harness the therapeutic potential of fibroblasts to address unmet medical needs and improve patient outcomes.

How the Company Makes Money

FibroBiologics, Inc. generates revenue primarily through the development and commercialization of its fibroblast-based therapies. The company may earn income through licensing agreements, partnerships with pharmaceutical companies, and the sale of its therapeutic products once they receive regulatory approval. Additionally, FibroBiologics might secure funding through research grants, equity investments, and collaborations with academic institutions or healthcare organizations. These partnerships and investments support the company's research and development efforts, facilitating the advancement of its innovative therapies to the market.

FibroBiologics, Inc. Financial Statement Overview

Summary

FibroBiologics, Inc. faces significant financial challenges with no revenue generation and increasing operational losses. Reliance on external funding raises sustainability concerns, though liquidity has improved slightly.

Income Statement

FibroBiologics, Inc. has consistently reported zero revenue, indicating no sales activity or market penetration. The company shows increasing losses over the years, with negative EBIT and Net Income margins worsening. This reflects high operational costs without corresponding revenue generation, a significant concern for financial sustainability.

Balance Sheet

The company has a weak equity position, with stockholders' equity improving from negative to positive but remaining low relative to liabilities. The debt-to-equity ratio is volatile due to fluctuating equity, posing significant financial risk. However, the increase in total assets and cash reserves signals some improvement in liquidity.

Cash Flow

Operating cash flow remains negative, indicating persistent cash burn. Free cash flow is also negative, driven by operational losses. Cash inflows from financing activities have been substantial, suggesting reliance on external funding. This raises concerns about long-term cash sustainability without revenue.

Breakdown
Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00
	Gross Profit
-437.00K	-94.00K	0.00	0.00
	EBIT
-8.89M	-4.47M	-1.58M	-1.17M
	EBITDA
-15.90M	-4.37M	-1.58M	0.00
	Net Income Common Stockholders
-16.48M	-5.12M	-1.58M	-1.17M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
9.16M	2.27M	407.00K	0.00
	Total Assets
11.82M	4.82M	468.00K	0.00
	Total Debt
1.75M	7.52M	1.52M	0.00
	Net Debt
-7.42M	5.26M	1.12M	0.00
	Total Liabilities
10.57M	8.82M	1.76M	0.00
	Stockholders Equity
1.25M	-4.00M	-1.29M	0.00
Cash Flow		Free Cash Flow
-6.90M	-4.07M	-1.41M	-1.17M
	Operating Cash Flow
-6.40M	-4.07M	-1.41M	-1.17M
	Investing Cash Flow
-495.00K	0.00	0.00	0.00
	Financing Cash Flow
13.79M	5.92M	1.82M	1.17M

FibroBiologics, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.12
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FBLG, the sentiment is Negative. The current price of 1.12 is above the 20-day moving average (MA) of 1.03, above the 50-day MA of 1.07, and below the 200-day MA of 2.27, indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 46.72 is Neutral, neither overbought nor oversold. The STOCH value of 33.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FBLG.

FibroBiologics, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	55 Neutral	$4.19B	-0.11	-14.97%	5.25%	17.22%	-61.84%
CNTB	49 Neutral	$44.83M	―	-58.89%	―	―	―
DYAI	46 Neutral	$36.71M	―	-139.16%	―	20.58%	15.90%
FBRX	42 Neutral	$46.86M	―	-80.82%	―	―	43.64%
FBLG	38 Underperform	$42.85M	―	-559.73%	―	―	―
OKYO	38 Underperform	$53.71M	―	0.00%	―	―	―
RVPH	28 Underperform	$41.60M	―	-916.17%	―	―	45.15%

FibroBiologics, Inc. Corporate Events

FibroBiologics Approves Executive Bonuses for 2024

On January 23, 2025, FibroBiologics, Inc. announced that its Compensation Committee and Board of Directors approved the 2024 fiscal year annual incentive bonuses for its executive officers. The updated Summary Compensation Table reveals the total compensation, including bonuses, stock options, and other earnings for the fiscal year ended December 31, 2024. Notably, a bonus of $75,000 was approved for Robert E. Hoffman, the Interim Chief Financial Officer.